CREDIT: Shutterstock There’s a new face on the block for blockbuster drugs, and it’s promising cheaper treatments. Just over a week ago, the FDA announced its approval of Zarxio, the first “biosimilar” in the United States, as an alternative to a drug used to treat chemotherapy patients susceptible to infection.